Health Trials

About this trial

The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, advanced balanced placebo design, patients with episodic migraine will receive six treatment conditions in a randomized order.

Eligibility criteria

Qualifiers

Adults (18-65 years)

≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria

Known episodic migraine (≥ 1 and < 15 headache days with features of migraine on at least 2-8 days per month for > 3 months) with and without aura and diagnosed before age 50

Previous or active use of triptans as acute treatment for migraine

Disqualifiers

Chronic migraine or history of chronic migraine in the last 12 months

Other concomitant primary headache types except for infrequent tension-type headache

Secondary headache disorders including medication overuse headache

Severe psychiatric, vascular or liver diseases

Trial design

Treatments tested in this trial

  • Active drug for acute migraine treatment
  • Placebo Oral Tablet

Treatment groups

128 Participants
are divided into 2 treatment groups

Locations

2
Dept. of Psychology and Behavioural Sciences8000, Aarhus C Denmark
Department of Neurology, Aarhus University Hospital8200, Aarhus N Denmark

Sponsors and collaborators

University of Aarhus

Lead sponsor

Source ClinicalTrials.gov